40 research outputs found
Efficacy of Milbemax (milbemycin oxime + praziquantel) in the treatment of dogs experimentally infected with Crenosoma vulpis
No full textCrenosoma vulpis, the fox lungworm, infects wild and domestic canids and is a cause of chronic respiratory disease in dogs in North America and Europe. The objective of this study was to determine the efficacy of milbemycin oxime (0.5mg/kg)/praziquantel (5mg/kg) (Milbemax; Novartis Animal Health, Inc.) against C. vulpis infection in a randomized, blinded, placebo-controlled study using experimentally infected dogs. Sixteen beagles (8 males, 8 females) were each given 100 infective third-stage larvae of C. vulpis. Fecal samples were examined for first-stage larvae by quantitative Baermann examination pre-exposure and at days 21, 28, 35, 42 and 49 post-infection (PI). All of the dogs were shedding larvae in the feces at 21 days PI. The dogs were randomly assigned to one of two groups. At 28 days PI, Group 1 (4 males, 4 females) received placebo only while Group 2 (4 males, 4 females) received a single treatment of milbemycin oxime (0.5mg/kg) and praziquantel (5mg/kg). The 16 dogs were euthanized and necropsied at 49 days PI. Lungs were removed, assessed for gross lesions (graded on a subjective scale 0-3 with 0 being normal) and C. vulpis were collected by lung-flush and counted. Samples of lung tissue were preserved for evaluation of histopathology and the lesions graded on a subjective scale (0-3 with 0 being normal). Gross and histopathology lesions were detected in all 8 untreated Group 1 dogs with mean subjective lesion scores of 1.8 ± 0.7 (range 1-3) and 3.0 ± 0.0 (range 3), respectively. Gross lesions were observed in 3/8 and histopathology lesions in all 8 of the treated Group 2 dogs with mean subjective lesion scores of 0.4 ± 0.5 (range 0-1) and 1.3 ± 0.4 (range 1-2), respectively. The mean (geometric) number for adult C. vulpis recovered in untreated dogs was 48.3 (range 25-70) compared with 0.65 (range 0-2) in animals treated with Milbemax. The resulting efficacy against C. vulpis was 98.7%. The number of C. vulpis was significantly lower for treated dogs than the burden in the untreated group (p=0.0002). A single dose of Milbemax (milbemycin oxime 0.5mg/kg+praziquantel 5mg/kg) was highly effective for the treatment of patent C. vulpis infection in dogs. A dosing interval for the prevention of clinical disease in dogs exposed to natural infections has not been established.journal articleresearch support, non-u.s. gov't2013 Dec 62013 09 20importe
Development of Crenosoma vulpis in the common garden snail Cornu aspersum: implications for epidemiological studies.
No full textBackground: Crenosoma vulpis (Dujardin, 1845), the fox lungworm, is a metastrongyloid affecting the respiratory tract of red foxes (Vulpes vulpes), dogs (Canis familiaris) and badgers (Meles meles) living in Europe and North America. The scant data available on the intermediate hosts of C. vulpis, as well as the limited information about the morphology of the larvae may jeopardise epidemiological studies on this parasite.
Methods: Suitability and developmental time of C. vulpis in the common garden snail Cornu aspersum (= Helix aspersa) was assessed at selected days post-infection (i.e. 3, 6, 10, 15, 20 and 180). Nematodes were preserved in 70 % ethanol, cleared and examined as temporary mounts in glycerol for morphological descriptions of first-and third-stage larvae. In addition, nematodes collected from the dog and the experimentally infected snails were molecularly analysed by the amplification of the nuclear 18S rRNA gene.
Results: Specimens of C. aspersum digested before the infection (n = 10) were negative for helminth infections. Out of 115 larvae recovered from infected gastropods (mean of 9.58 larvae per snail), 36 (31.3 %) were localised in the foot and 79 (68.7 %) in the viscera. The 18S rDNA sequences obtained from larvae collected from the dog and the snail tissues displayed 100 % identity to the nucleotide sequence of C. vulpis.
Conclusions: Cornu aspersum is herein reported for the first time as a suitable intermediate host of C. vulpis. This snail species may play an important role for the infection of animals living in regions of the Mediterranean basin. In addition, this study provides more details on the morphological descriptions of L1 and L3 and supports future investigations on the epidemiology of this little known parasite
Distribution of Crenosoma vulpis and Eucoleus aerophilus in the lung of free-ranging red foxes (Vulpes vulpes)
No full textCrenosoma vulpis and Eucoleus aerophilus are nematode parasites that can cause verminous pneumonia in wild carnivores. There is a paucity of information regarding the distribution of parasites in the lungs and the relationship between histopathological and parasitological diagnoses in naturally infected foxes. The objectives of this study were: first, to study the lobar and airway distribution of C. vulpis and E. aerophilus in wild red foxes and second, to investigate the relationship between fecal and histopathological diagnoses. Samples from 6 sites of the lung and fecal contents were obtained from 51 wild foxes in Prince Edward Island. By fecal examination, 78.4% of wild foxes tested positive for C. vulpis and 68.6% for E. aerophilus. In contrast, 66.6% and 49% of foxes had histopathological evidence of C. vulpis and E. aerophilus in the lungs, respectively. Anatomically, C. vulpis was observed in the small bronchi and bronchioles of all pulmonary lobes whereas E. aerophilus was restricted to the large bronchi and the caudal lobes. Affected airways exhibited severe epithelial glandular hyperplasia and bronchiolar mucous metaplasia. It was concluded that C. vulpis is widely distributed in airways of all pulmonary lobes, whereas E. aerophilus is mainly restricted to the bronchi of caudal lobes. Also, this study showed that histological examination of lung underestimates the infection with E. aerophilus.PUBM: Print; JID: 9011490; ppublishSource type: Electronic(1
Infectivity of gastropod-shed third-stage larvae of Angiostrongylus vasorum and Crenosoma vulpis to dogs
No full textBackground
Metastrongyloid parasites Angiostrongylus vasorum and Crenosoma vulpis infect wild and domestic canids and are important pathogens in dogs. Recent studies indicate that gastropod intermediate hosts infected with various metastrongyloids spontaneously shed infective third-stage larvae (L3) into the environment via feces and mucus under laboratory conditions. Shed L3 retain motility up to 120 days, but whether they retain infectivity was unknown.
Methods
To assess the infectivity of shed L3, the heart/lungs of six red foxes (Vulpes vulpes) were obtained from trappers in Newfoundland, Canada. Lungs were examined for first-stage larvae (L1) by the Baermann technique. A high number of viable A. vasorum L1 and a low number of C. vulpis L1 were recovered from one fox; these were used to infect naïve laboratory-raised Limax maximus. L3 recovered from slugs by artificial digestion were fed to two naïve purpose-bred research beagles (100 L3/dog). L1 shed by these two dogs was used to infect 546 L. maximus (2000–10,000 L1/slug). L3 shedding was induced by anesthetizing slugs in soda water and transferring them into warm (45 °C) tap water for at least 8 h. Shed L3 recovered from slugs were aliquoted on romaine lettuce in six-well tissue culture plates (80–500 L3/well) and stored at 16 °C/75% relative humidity. Four naïve research beagles were then exposed to 100 L3/dog from larvae stored for 0, 2, 4, or 8 weeks, respectively, after shedding.
Results
All four dogs began shedding C. vulpis L1 by 26–36 days post-infection (PI). All four dogs began shedding A. vasorum L1 by 50 days PI.
Conclusions
L3 infectivity for the definitive host was retained in both metastrongyloids, indicating the potential for natural infection in dogs through exposure from environmental contamination. As an additional exposure route, eating or licking plant or other material(s) contaminated with metastrongyloid L3 could dramatically increase the number of dogs at risk of infection from these parasites.University of Prince Edward IslandElanco (United States
Crenosoma vulpis in wild and domestic carnivores from Italy: a morphological and molecular study
No full textCrenosoma vulpis is a metastrongyloid nematode primarily associated with respiratory tract infections of red foxes in North America and Europe. Sporadic cases have also been reported in domestic dogs. The present study aimed to provide morphological, molecular, and epidemiological data on the geographical distribution of this nematode throughout Italy. From 2012 to 2014, 12 of the 138 foxes examined, three dogs and one badger scored positive for C. vulpis. Forty adults were isolated from foxes and the badger, whereas first-stage larvae were detected in the three dogs. All specimens were morphologically identified as C. vulpis, and 28 nematodes were also molecularly characterized by sequencing mitochondrial (12S ribosomal DNA (rDNA)) and nuclear (18S rDNA) ribosomal genes. Four haplotypes were identified based on the 12S rDNA target gene, with the most representative (78.5 %) designated as haplotype I. No genetic variability was detected for the 18S rDNA gene. The molecular identification was consistent with the distinct separation of species-specific clades inferred by the phylogenetic analyses of both mitochondrial and ribosomal genes. Data herein reported indicates that C. vulpis has a wide distribution in foxes from southern Italy, and it also occurs in dogs from southern and northern regions of the country. Practitioners should consider the occurrence of this nematode in the differential diagnosis of canine respiratory disease, particularly in dogs living close to rural areas where foxes are present
An in vitro larval motility assay characterizes anthelmintic efficacy against Crenosoma vulpis, Angiostrongylus vasorum, and Aelurostrongylus abstrusus
No full textOBJECTIVE
This study determined the in vitro efficacy of 6 common anthelmintics (eprinomectin, ivermectin, milbemycin oxime, moxidectin, selamectin, and fenbendazole) on motility (viability) of infectious third-stage larvae (L3) of Crenosoma vulpis, Angiostrongylus vasorum, and Aelurostrongylus abstrusus, which are important causes of canine and feline cardiopulmonary disease.
SAMPLES
First-stage larvae (L1) from C vulpis, An vasorum, and Ae abstrusus.
PROCEDURES
Naïve Limax maximus slugs were fed 1,000 to 2,000 L1 and held at 16 °C for at least 4 weeks to produce live L3. Approximately 50 to 100 L3/well were subsequently incubated in culture media alone or media containing 6 separate test anthelmintics at 4 concentrations, to bracket expected in vivo drug plasma levels in anthelmintic-treated dogs and cats. Drug effects on L3 motility (viability) were analyzed by multilevel logistic models, generating dose-response relationships. Experiments were completed 1-9/2019.
RESULTS
Drug concentration estimates corresponding to a 50% larval mortality rate identified that C vulpis was the most sensitive species to the anthelmintics tested. Ae abstrusus was most susceptible to moxidectin and selamectin, while An vasorum was insusceptible to all anthelmintics tested, except for selamectin at high drug concentrations.
CLINICAL RELEVANCE
The in vitro anthelmintic response to antiparasitic agents may guide and improve disease therapy and prevention. Considering the observed lack of efficacy against L3, monthly anthelmintic treatment for protection against An vasorum infection in dogs would primarily rely on the anthelmintic’s adulticidal activity. Maximal preventive control for An vasorum would, therefore, require at least 1 treatment administered a minimum of 1 week after the end of the transmission season
Crenosoma vulpis and the domestic dog: A study of prevalence on Prince Edward Island and of new diagnostic approaches
No full textCrenosoma vulpis is a metastrongyloid lung parasite which infects the bronchioles, bronchi, and trachea of wild and domestic canids and other carnivores. The infection cannot be diagnosed with standard fecal flotation examinations carried out at most veterinary clinics. Clinical signs of C. vulpis infection include chronic cough, wheezing, and decreased quality of life and closely mimic signs of canine allergic respiratory disease, which appears to be relatively common in dogs in the Atlantic Canadian region. Suspicions that the infection may have been previously misdiagnosed led to a study to determine the impact of C. vulpis infection on dogs on Prince Edward Island. The first objective was to determine the estimated prevalence of C. vulpis infection in PEI dogs. The second objective was to determine the proportion of PEI dogs infected with C. vulpis among those with clinical signs such as chronic cough. The third objective of the study consisted of developing a more sensitive diagnostic test, an enzyme-linked immunosorbent assay (ELISA), for the detection of antibodies to C. vulpis antigens in serum. (Abstract shortened by UMI.).Source: Masters Abstracts International, Volume: 37-03, page: 0883.Adviser: Gary Conboy
Diversity and ecology of pulmonary metastrongyloidosis in coyotes (Canis latrans) of Nova Scotia, Canada
No full textCoyotes (Canis latrans) are widely distributed in North America and were first recorded in Nova Scotia, Canada, in 1977. Although coyotes are host to a number of parasitic helminths, the parasite fauna of coyotes from Nova Scotia has not been previously investigated. The objectives of this study were to determine geographical range, prevalence, mean intensity, and abundance of metastrongyloid helminth parasites of the pulmonary system (Crenosoma vulpis, Oslerus osleri) in coyotes from Nova Scotia and to investigate whether prevalence, mean intensity, and abundance were consistent among different age classes of this mammal. In addition, hearts and pulmonary arteries were examined for the presence of Angiostrongylus vasorum (French heartworm) and Dirofilaria immitis (heartworm) to determine whether these heartworms had spread to Nova Scotia. A total of 235 coyotes were collected from trappers in the 2010–2011 season. Heart and lungs were removed from coyotes and examined for parasites by gross examination and lungflush. Canine teeth from lower jaws were removed to assess the age class of each coyote. Crenosoma vulpis and O. osleri were found in 31% and 37% of coyotes, respectively. There was a mean intensity of 8.8 adult C. vulpis and 9.5 nodules of O. osleri in infected coyotes across all age classes, with a tendency toward higher worm burdens in juvenile animals; significant differences were observed only for C. vulpis. There was a mean abundance of 2.7 adult C. vulpis and 3.5 nodules of O. osleri in coyotes sampled across all age classes, with significantly higher numbers of each species of worm in juveniles. Dirofilaria immitis and A. vasorum were not detected. The life history implications of these findings are discussed in relation to the possibility of parasite transmission to domestic dogs
Natural infections of Crenosoma vulpis and Angiostrongylus vasorum in dogs in Atlantic Canada and their treatment with milbemycin oxime
No full textMilbemycin oxime was used to treat dogs with natural infections of the fox lungworm, Crenosoma vulpis and the French heartworm, Angiostrongylus vasorum. Crenosomosis was identified in 42 of 202 dogs with clinical signs of coughing, dyspnoea or exercise intolerance by a Baermann analysis of faecal samples taken between October 2000 and October 2001. It occurred throughout Atlantic Canada (New Brunswick, Newfoundland, Nova Scotia and Prince Edward Island). The clinical signs resolved and shedding of larvae in faeces ceased in all 32 Crenosoma-infected dogs given a single oral dose of 0.5 mg/kg milbemycin oxime for which the results of faecal examinations were available. Angiostrongylosis was identified in 16 of the 202 dogs and was restricted to the Avalon peninsula of Newfoundland, where 67 dogs were tested. The clinical signs resolved and shedding of larvae ceased in 14 of the 16 dogs treated with four, weekly oral doses of 0.5 mg/kg milbemycin oxime. One dog with severe clinical signs died during the course of treatment and one owner failed to provide a faecal sample from their dog but reported that the clinical signs had resolved.Source type: Electronic(1
Efficacy and Safety of Two Dosages of Canrenone as Add-On Therapy in Hypertensive Patients Taking Ace-Inhibitors or Angiotensin II Receptor Blockers and Hydrochlorothiazide at Maximum Dosage in a Randomized Clinical Trial: The ESCAPE-IT Trial
No full textAim: To evaluate the effects of canrenone as add-on therapy in patients already treated with angiotensin-converting enzyme inhibitors (ACE-I) or angiotensin II receptor blockers (ARBs) and hydrochlorothiazide at the maximum dosage (25 mg/d). Method: In this randomized, open-label, controlled trial, we enrolled 175 Caucasian patients with essential hypertension not well controlled by concomitant ACE-I or ARBs and hydrochlorothiazide. At baseline, 87 patients (57 males and 30 females) were randomized to add canrenone 50 mg, and 88 (56 males and 32 females) patients to canrenone 100 mg, once a day, for 3 months. At baseline and after 3 months, we evaluated blood pressure (BP), pulse pressure (PP), heart rate (HR), fasting plasma glucose (FPG), homeostasis model assessment insulin (HOMA Index), lipid profile, electrolytes, uric acid, estimated glomerular filtration rate (eGFR), plasma urea, aldosterone, B-type natriuretic peptide (BNP), and galectin-3. Results: Blood pressure decreased with both dosages of canrenone, with a better effect with canrenone 100 mg (−20.26 vs −23.68 mm Hg for SBP, and −10.58 vs −12.38 mm Hg for DBP), without a clinically relevant increase in potassium levels. We did not observe any differences regarding FPG or HOMA Index, nor of lipid profile, with the exception of triglycerides, which increased compared to baseline with canrenone 50 mg (+0.25 vs +0.34 mEq/L). Creatinine slightly increased with canrenone 100 mg (+0.02 vs +0.05 mg/dL), although no variations of eGFR were observed in neither groups. There was an increase in aldosterone levels with canrenone 50 mg. No changes in BNP or galectin-3 were recorded. Conclusion: Both canrenone dosages gave a decrease in blood pressure, with a better effect with the higher dose, with only a slight increase in potassium and creatinine levels, which were not clinically relevant. Clinical Trials Registration Eudract number: 2010-023606-13; ClinicalTrials.gov NCT02687178
